Payment overview · 2025
General Payments
$369.68
24 reported records · 9 companies
Healthcare provider profile · identity verified
Gafar Ajani Adesoji, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHAVEN, MS · NPI 1861414708
Verified facts
What the public records show
CMS Open Payments records show Gafar Ajani Adesoji, M.D received $369.68 in general payments during 2025 across 24 reported records.
Lilly USA, LLC accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.32 | 38.0% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $60.91 | 16.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.29 | 14.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $27.55 | 7.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.33 | 6.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.73 | 4.5% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $16.42 | 4.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.69 | 4.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.44 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $369.68 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $108.87 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.94 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $60.91 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.29 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 235 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 277 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
235 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
277 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 626 | 180 |
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 138 |
| Ozempic | Semaglutide | 277 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 85 |
| Jardiance | Empagliflozin | 235 | 50 |
| Losartan Potassium | Losartan Potassium | 229 | 77 |
| Hydralazine Hcl | Hydralazine Hcl | 211 | 76 |
| Metformin Hcl | Metformin Hcl | 189 | 59 |
| Simvastatin | Simvastatin | 179 | 51 |
| Carvedilol | Carvedilol | 174 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 46 |
| Potassium Chloride | Potassium Chloride | 169 | 41 |
| Glipizide | Glipizide | 160 | 46 |
| Gabapentin | Gabapentin | 154 | 59 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 154 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 152 | 46 |
| Furosemide | Furosemide | 135 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 39 |
| Lisinopril | Lisinopril | 113 | 38 |
| Omeprazole | Omeprazole | 109 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 35 |
| Montelukast Sodium | Montelukast Sodium | 96 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 26 |
| Meloxicam | Meloxicam | 89 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 88 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 27 |
| Allopurinol | Allopurinol | 76 | 26 |
| Mounjaro | Tirzepatide | 76 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 20 |
| Eliquis | Apixaban | 69 | 15 |
| Mirtazapine | Mirtazapine | 67 | 20 |
| Glipizide Er | Glipizide | 66 | 21 |
| Glimepiride | Glimepiride | 58 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 19 |
| Buspirone Hcl | Buspirone Hcl | 54 | 12 |
| Linzess | Linaclotide | 52 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 15 |
| Clonidine Hcl | Clonidine Hcl | 46 | 18 |
| Bumetanide | Bumetanide | 45 | 15 |
| Chlorthalidone | Chlorthalidone | 44 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 11 |
| Famotidine | Famotidine | 41 | 18 |
| Atenolol | Atenolol | 39 | 12 |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Ezetimibe | Ezetimibe | 37 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 37 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 14 |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | 11 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | 11 |
| Amoxicillin | Amoxicillin | 31 | 26 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 30 | suppressed |
| Metolazone | Metolazone | 30 | 11 |
| Colchicine | Colchicine | 29 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 25 | suppressed |
| Azithromycin | Azithromycin | 25 | 20 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Topamax | Topiramate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $369.68 · 24 records | Lilly USA, LLC | AREXVY, AUSTEDO XR, BEXSERO, CAPVAXIVE, Doc Band, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Korlym, M-M-R II, MOUNJARO, Ozempic, ROTATEQ, Rybelsus, SHINGRIX, VAXNEUVANCE, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error